J 2017

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance

SANDECKÁ, Viera; Roman HÁJEK; Luděk POUR; I. SPICKA; V. SCUDLA et. al.

Základní údaje

Originální název

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance

Autoři

SANDECKÁ, Viera; Roman HÁJEK; Luděk POUR; I. SPICKA; V. SCUDLA; E. GREGORA; J. RADOCHA; L. WALTEROVA; P. KESSLER; L. ZAHRADOVA; D. ADAMOVA; K. VALENTOVA; I. VONKE; J. OBERNAUEROVA; D. STAROSTKA; M. WROBEL; Lucie BROŽOVÁ; Jiří JARKOVSKÝ ORCID; Aneta MIKULÁŠOVÁ; L. RIHOVA; Sabina ŠEVČÍKOVÁ; J. STRAUB; J. MINARIK; Zdeněk ADAM; Marta KREJČÍ; Zdeněk KRÁL a V. MAISNAR

Vydání

European Journal of Haematology, Hoboken, Wiley-Blackwell, 2017, 0902-4441

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.595

Kód RIV

RIV/00216224:14110/17:00098729

Organizační jednotka

Lékařská fakulta

UT WoS

000403724300010

EID Scopus

2-s2.0-85018904802

Klíčová slova anglicky

monoclonal gammopathy; multiple myeloma; progression; risk factors

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 18. 3. 2018 16:41, Soňa Böhmová

Anotace

V originále

IntroductionMonoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition with a risk of malignant conversion. Patients and methodsWith the aim to estimate the cumulative risk MGUS progression to hematologic malignancies, we analyzed a nationwide population-basedcohort of 1887 MGUS patients from the Czech Registry of Monoclonal Gammopathies (RMG) between 2007 and 2013. ResultsDuring the follow-up period (median 4years; range 0.6-34.8), progression to hematologic malignancies was observed in 8.6% (162 of 1887) of patients. Factors associated with progression were as follows: M-protein concentration 1.5g/dL, pathological sFLC (<0.26 or >1.65) ratio, bone marrow plasma cells (BMPCs) in cytology >5%, immunoparesis, age 69years, and the level of serum hemoglobin at baseline <12.0g/dL. Combining these factors, we propose a new risk model (CMG model). The risk of progression at 10years was 1.6%, 16.9%, 22.9%, 39.4%, and 52.3%, respectively, if 0 (reference group), one, two, three, or four to five risk factors are present (P<.001) with HR 63 times higher compared to the reference MGUS group. ConclusionThe new CMG model was established with an advantage for better identification of MGUS patients at low risk.